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ABSTRACT: The structural changes caused by the substitution of the aromatic moiety in (2S)-2-benzyl-3-
dehydroquinic acids and its epimers in C2 by electron-withdrawing or electron-donating groups in type II 
dehydroquinase enzyme from M. tuberculosis and H. pylori has been investigated by structural and 
computational studies. Both compounds are reversible competitive inhibitors of this enzyme, which is 
essential in these pathogenic bacteria. The crystal structure of M. tuberculosis and H. pylori in complex with 
(2S)-2-(4-methoxy)benzyl- and (2S)-2-perfluorobenzyl-3-dehydroquinic acids have been solved at 2.0, 2.3, 
2.0 and 1.9 Å, respectively. The crystal structure of M. tuberculosis in complex with (2R)-2-(benzothiophen-
5-yl)methyl-3-dehydroquinic acid is also reported at 1.5 Å. These crystal structures reveal key differences in 
the conformation of the flexible loop of the two enzymes – a difference that depends on the presence of 
electron-withdrawing or electron-donating groups in the aromatic moiety of the inhibitors. This loop closes 
over the active site after substrate binding and its flexibility is essential for the function of the enzyme. 
These differences have also been investigated by molecular dynamics simulations in an effort to understand 
the significant inhibition potency differences observed between some of these compounds and also to obtain 
more information about the possible movements of the loop. These computational studies have also allowed 
us to identify key structural factors of the H. pylori loop that could explain its reduced flexibility in 
comparison to the M. tuberculosis loop, specifically by the formation of a key salt bridge between the side 
chains of residues Asp18 and Arg20.  
 
INTRODUCTION 
In the past few years, our research group has been studying the possible development of new antibiotics by 
inhibition of the third enzyme of the shikimic acid pathway, dehydroquinase (3-dehydroquinate dehydratase, 
DHQ, EC 4.2.1.10). In particular, we have focused on the inhibition of two pathogenic bacteria, 
Mycobacterium tuberculosis, the causative agent of tuberculosis, and Helicobacter pylori, the causative 
agent of gastric and duodenal ulcers, which has also been classified as a type I carcinogen. The DHQ 
enzymes from these bacteria are encoded by the genes aroD and aroQ/aroD, respectively.
1,2
 There are two 
distinct dehydroquinases, known as type I and type II, which have different biochemical and biophysical 
3 
properties and exhibit no significant sequence or structural similarity. Both sub-types catalyze the same 
overall reaction through independent mechanisms and with opposite stereochemistry.
3,4
  
The type II enzyme, which is present in Mycobacterium tuberculosis and Helicobacter pylori, catalyze the 
anti elimination of water involving the loss of the more acidic pro-S hydrogen from C2 of 3-dehydroquinic 
acid (1) to form 3-dehydroshikimic acid (2) (Scheme 1).
5,6
 Two residues, an arginine (Arg19 and Arg17 in 
M. tuberculosis and H. pylori, respectively) and a tyrosine (Tyr24 and Tyr22 in M. tuberculosis and H. 
pylori, respectively), have been identified by chemical modification and site-directed mutagenesis studies as 
being essential for enzyme activity.
7,8 
Both residues are located in the flexible loop that closes over the 
active site upon substrate binding. The elimination proceeds through a stepwise E1CB mechanism
5
 involving 
an enol intermediate 3, which is stabilized by a conserved water molecule that interacts through hydrogen-
bonding with a conserved asparagine (Asn12 and Asn10 in M. tuberculosis and H. pylori, respectively), the 
carbonyl group of a conserved proline (Pro11 and Pro9 in M. tuberculosis and H. pylori, respectively), and 
the main-chain amide of Gly78 in M. tuberculosis or Ala19 in H. pylori (Scheme 1).
6
 The reaction is 
initiated by the essential tyrosine and the final step is the acid-catalyzed elimination of the C1 hydroxyl 
group  a reaction mediated by a conserved histidine acting as a proton donor.  
We have shown previously that the substitution of either the pro-R or pro-S hydrogen from C2 of 1 by a 
functionalized benzyl group provides good reversible competitive inhibitors of this enzyme (Table 1).
9
 The 
resolution of the crystal structures of the binary complexes between DHQ2 from M. tuberculosis (DHQ2-
Mt) and H. pylori (DHQ2-Hp) and one of the most potent inhibitors of the 2R-substituted derivatives 5, the 
4-methoxybenzyl derivative 5a, which has Ki values of 26 nM and 170 nM, respectively, reveal that the 
essential arginine is expelled from the active site and faces away from the essential tyrosine.
10
 Molecular 
dynamics simulations suggest that the benzyl groups of ligands 5 inactivate the enzyme by causing a 
significant conformational change in the flexible loop – a change that prevents appropriate orientation of the 
tyrosine for proton abstraction.
10
 It is important to highlight that the 2R-substituted derivatives 5 still contain 
the axial hydrogen that could be removed by the essential tyrosine, the residue that triggers the dehydration 
reaction. 
4 
For the DHQ2-Mt enzyme, the biological results showed that the substitution of either the pro-R or pro-S 
hydrogen from C2 of 1 by either an electron-rich or electron-withdrawing benzyl group provides good 
reversible competitive inhibitors, all of which are in the low nanomolar range (Table 1). For the DHQ2-Hp 
enzyme, the differences in inhibition potencies between the 2R-substituted derivatives 5 and the 2S-
substituted derivatives 4 are more pronounced, with the 2R-substituted derivatives 5 being more potent in 
general. However, this trend is broken by the pentafluorobenzyl analog 5c, which showed a significantly 
higher Ki (2.6 µM) than the other 2R-substituted derivatives 5a and 5b (0.16 µM and 0.17 µM, respectively). 
Intrigued by the fact that the substitution of either the pro-R or pro-S hydrogen from C2 of 1 by either an 
electron-rich or electron-withdrawing benzyl group provides good reversible competitive inhibitors of these 
enzymes, in particular for DHQ2-Mt, we decided to gain further insights into the interaction of the 2S-
substituted derivatives 4 and to analyze the differences in the binding mode of the two series’, compounds 4 
and 5. To this end, the crystal structures of both DHQ2 enzymes in complex with two 2S-substituted 
derivatives 4, the 4-methoxybenzyl derivative 4a, which has an electron-rich aromatic ring, and the 
pentafluorobenzyl analog 4c, which has an electron-withdrawing aromatic ring, are reported along with the 
binary complex between DHQ2-Mt and 2R-benzothiophen-5-yl derivative 5b. In addition, the loop 
conformation differences observed with inhibitors 4a and 4c were also studied by molecular dynamics (MD) 
simulations in order to gain an insight into the role that the type of substituent of the aromatic moiety plays 
in the binding mode of the inhibitors. Moreover, these MD simulations allowed us to understand the key 
structural differences responsible for the reduced mobility of the H. pylori loop and the significant 
differences in inhibition potency observed for the 2R-pentafluorobenzyl analog 5c between the two DHQ2 
enzymes.  
 
RESULTS AND DISCUSSION 
Structural Studies. The crystal structures of the 2S-4-methoxybenzyl compound 4a and the 2S-
pentafluorobenzyl derivative 4c in complex with DHQ2-Mt and DHQ2-Hp were solved at 2.0, 2.3, 2.0 and 
1.9 Å, respectively. In addition, the crystal structure of the binary complex between 2R-benzothiophen-5-yl 
derivative 5b and DHQ2-Mt was also solved at 1.55 Å. Crystals of the DHQ2-Hp/5b complex did not 
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diffract well enough to collect X-ray diffraction data. The binary complexes DHQ2-Hp/4a, DHQ2-Hp/4c 
and DHQ2-Mt/4c were obtained by co-crystallization and the DHQ2-Mt/4a and DHQ2-Mt/5b binary 
complex crystals were obtained by soaking apo-DHQ2-Mt
4
 crystals. Crystals were flash-frozen directly 
from the crystallization mixtures by rapid immersion in liquid nitrogen. The crystallization conditions 
contain enough amount of cryo-protectant (PEG or MPD) to directly freeze the protein crystals in liquid 
nitrogen without further manipulation. X-ray diffraction data were collected from crystals cryo-cooled in a 
stream of cold nitrogen gas (100 K) at ambient pressure using synchrotron radiation, and were processed. 
All structures were determined by molecular replacement. For the H. pylori enzyme, the crystal structure of 
DHQ2-Hp bound to citrate described by Lapthorn et al. (PDB entry 2C4V
11
) was used as a search model 
and was refined. For the M. tuberculosis enzyme, the crystal structure of DHQ2-Mt bound to 3-
hydroxyimino quinic acid (PDB entry 1H0S)
12
 was employed. A summary of the statistics following data 
reduction and processing is given in Table 2.   
The binary complexes DHQ2-Mt/4a, DHQ2-Mt/4c and DHQ2-Mt/5b contain a single DHQ2-Mt 
molecule in the crystallographic asymmetric unit (Figures 1a–c), while DHQ2-Hp/4a and DHQ2-Hp/4c 
complexes crystallized with three nearly identical copies of the inhibitor-protein complex in the asymmetric 
unit (with rmsd between the protein α carbons < 0.4 Å) (designated molecules A, B & C, Figures 1d–e). 
All structures refine with good geometric parameters and clear electron density is visible for all amino 
acids with the exception of those of the very C-terminal amino acids of the H. pylori protein and certain 
residues of the flexible substrate-covering loop of all five structures. The flexibility of this loop is essential 
for the function of the enzyme and therefore the presence in the crystals of some disorder in this loop is not 
surprising. Nevertheless, we were able to model the loop completely in four of the five structures, with the 
exception being that of the DHQ2-Mt/5b binary complex (Figure 1c). We used these modeled 
conformations in molecular dynamics simulation studies to obtain further information about the possible 
movements of the loop (see below). 
1. DHQ2-Mt/4a Binary Complex: Comparison of this crystal structure with our solved crystal structure for 
DHQ2-Mt in complex with its epimer on C2, i.e. compound 5a (PDB entry 2XB8
10
), shows that both 
structures are virtually identical (0.8 Å root-mean-square difference for C-alpha atoms after superposition) 
6 
with the exception of the loop that closes over the active site upon substrate binding (see supporting 
information). In the crystal structure reported here, the loop conformation changes significantly – it moves 
up by 4.5 Å in relation to its position in the DHQ2-Mt/5a binary complex to give a more open conformation. 
This displacement is caused by the axial benzyl group of compound 4a, which prevents the appropriate 
approach of the essential Tyr24 of the loop to the conserved Arg108 of the active site, a residue that has a 
significant effect on lowering the pKa of Tyr24.
6,10
 In this more open conformation of the loop, there is 
room for the side chain of the essential Arg19 to point towards the active site. Although the electron density 
is not completely conclusive, we modeled the side chain of Arg19 to point inwards with the guanidine group 
located approximately 6 Å from Tyr24. This situation is in contrast to the epimer, compound 5a, where the 
Arg19 side chain is expelled from the active site. In addition, a ππ stacking interaction between the 
aromatic rings of Tyr24 and ligand 4a is not observed, but this interaction is evident for its epimer. The axial 
disposition of the benzyl group of C2 prevents its location in the vicinity of the conserved residues Leu13 
and Leu16, as observed for its isomer compound 5a. The benzyl group is therefore displaced away from this 
apolar pocket of DHQ2 and is located in an intermediate subpocket close to the carbon side chain of Arg15 
and Asn12, a region that has been identified as important for the design and efficacy of inhibitors.
13
 
2. DHQ2-Mt/4c Binary Complex: With the exception of the two poorly ordered amino acids located on the 
loop, Arg19 and Glu20, this crystal structure is virtually identical to our recently solved crystal structure of 
DHQ2-Mt in complex with compound 5a (PDB entry 2XB8
10
) (0.4 Å root-mean-square difference for C-
alpha atoms after superposition) (see supporting information). In the structure reported here, the catalytic 
Tyr24 is stabilized by a set of favorable hydrogen-bonding interactions with Arg108 and possibly with 
Glu20 (Figure 2). The main differences in the ligand binding are in the position of the benzylic side chain. In 
this case, the perfluorobenzyl moiety of 4c establishes an offset ππ stacking interaction with the side chain 
of Tyr24. The guanidinium group of Arg19 has been modeled into density near to the perfluorobenzyl 
moiety of 4c, which may form a favorable electrostatic interaction. Moreover, the perfluorobenzyl moiety 
has a series of CarylF···HC attractive contacts with the side chains of Leu13, Leu16 and Ile102 and the 
carbon side chain of Arg15 and Asn12 (3.3  3.9 Å, see also supporting information). Few examples of ππ 
7 
stacking interactions between perfluorophenyl moieties and the aromatic ring of phenylalanine or tyrosine 
residues have been reported.
14-16
 
Two relevant water molecules are shown in the active site (Figure 2). One of them is the essential water 
molecule involved in the catalytic mechanism and this forms a hydrogen bond with the carbonyl group of 
4c. The second water molecule interacts through hydrogen-bonding with one of the fluorine atoms of the 
perfluorobenzyl moiety of 4c and also with the side chain of Arg108, Arg112 and Asp88 of the neighboring 
subunit (not shown). 
Comparison of the crystal structures of DHQ2-Mt/4a and DHQ2-Mt/4c binary complexes shows that the 
binding modes of ligands 4a and 4c are quite similar (see supporting information), but the different 
substitution of the aromatic moiety causes different conformational changes of the loop. In both cases, a 
disruption in the appropriate conformation of the loop for catalysis is obtained, which might explain their 
similar inhibition constants (Ki of 100 nM and 74 nM, respectively). The electron-deficient benzyl group of 
ligand 4c is responsible for a strong ππ stacking interaction with Tyr24 and a possible favorable 
electrostatic interaction with the guadinium group of Arg19. These attractive interactions favor a stable 
closed form of the loop, the flexibility of which is clearly reduced. These two attractive interactions are not 
present in binding ligand 4a, which has an electron-rich aromatic ring. Thus, the 4-methoxybenzyl moiety 
prevents the approach of Tyr24 for proton abstraction and a more open conformation of the loop is 
preferred.  
3. DHQ2-Mt/5b Binary Complex: In this crystal structure, seven amino acids located on the loop (residues 
19–25) are not visible. Calculated maps showed clear high electron density for the inhibitor molecule 5b 
(Figure 1c), indicating that the benzothiophenyl group is located approximately perpendicular to the 
cyclohexane ring and with its sulfur atom orientated towards the flexible loop. In the crystal structure 
reported here, the benzothiophenyl ring rotates by about 43º toward the tyrosine of the loop and causes a 
change in the orientation of the side chain of Leu16 (see supporting information). This shift allows the 
establishment of CHπ interactions between the side chain of Leu16 and the benzothiophenyl ring, which is 
more electron-rich than the 4-methoxyphenyl one. With the benzothiophenyl ring located approximately 
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perpendicular to the cyclohexane ring, the closure of the active site is avoided by preventing hydrogen-
bonding interaction between the essential Tyr24 and Arg108. 
4. DHQ2-Hp/4a Binary Complex: As for compound 5a, the essential Arg17 is expelled from the active site 
to face away from Tyr22. Surprisingly, despite the axial disposition of the 4-methoxybenzyl group of ligand 
4a, only a small shift of the loop (~1.0 Å) is observed. In fact, the position of ligand 4a is slightly offset in 
relation to 5a in order to accommodate the 4-methoxybenzyl moiety within the active site without altering 
the loop conformation. We modeled the side chain of Tyr22 in density parallel to the benzyl group of the 
inhibitor. The results suggest that for the DHQ2-Hp enzyme, the disposition of the essential Tyr22 is 
preferred when the essential Arg17 is either outside the active site or is too far away to interact with Tyr22. 
This finding supports the idea that the essential arginine of the loop has a crucial role in the control of the 
appropriate orientation of the essential tyrosine for proton abstraction.
10
 
5. DHQ2-Hp/4c Binary Complex: As for ligands 4a and 5a, the essential Arg17 appears to point away from 
the active site and the perfluorobenzyl group of 4c interacts by ππ stacking (parallel-displaced) with the 
essential Tyr22 (Figure 3). The loop is slightly more closed than for ligand 4a (~1.4 Å). The perfluorobenzyl 
group of 4c shows several favorable hydrogen-bonding interactions with three nearby bound water 
molecules (W22, W69 and W230). In addition, a series of CarylF···HC attractive contacts with the side 
chains of Leu11, Leu14 and Leu103 and the carbon side chain of Asn10 are apparent (3.1  3.6 Å, see also 
supporting information). 
 
The structural studies reported here still leave some unresolved issues with regard to the binding mode of 
2S-2-benzyl derivatives 4. The 2S-2-perfluorobenzyl derivative 4c seems to close completely the active site 
of the DHQ2-Mt enzyme with the side chains of Tyr24 and Arg19 inside of the active site. However, this 
does not seem to occur for the DHQ2-Hp enzyme. Moreover, the binding mode of the 2S-4-methoxybenzyl 
derivative 4a in the active site of the DHQ2-Hp is similar to that of its epimer 5a, although they show about 
10-fold differences in inhibition constant that are not found for the DHQ2-Mt enzyme. In addition, 2R-2-
perfluorobenzyl derivative 5c shows a significantly higher Ki (2.6 µM) against the DHQ2-Hp enzyme in 
comparison to the other components of the series (0.160.17 µM), a situation that does not occur for the M. 
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tuberculosis enzyme. We considered that the reasons for some of these differences could be found in the 
different flexibility of the two loops. In order to gain an insight into these unanswered questions, we decided 
to carry out a further analysis of the dynamic behavior of the binding mode of these inhibitors in the active 
site of the DHQ2 by MD simulations studies. 
 
Molecular Dynamics Simulations Studies. In order to analyze the relevance of the potential electrostatic 
interaction observed in the DHQ2-Mt/4c binary complex (PDB entry 4B6P) between Arg19 and the 
perfluorobenzyl moiety of 4c and to understand why the same behavior is not observed in the binary 
complex with the DHQ2-Hp enzyme, MD simulations were carried out. Firstly, the DHQ2-Mt/4c binary 
complex was subjected to 10 ns of simulation in order to analyze the dynamic behavior of its ππ stacking 
and potential electrostatic interaction with Tyr24 and Arg19, respectively. Moreover, starting from the 
DHQ2-Mt/4c complex, ligand 4c was replaced by 4a, which has an electron-rich ring, and the final complex 
was submitted to 10 ns of simulation in order to analyze the dynamic behavior of this ligand replacement. 
Finally, a similar study was performed for the DHQ2-Hp enzyme using the PDB entry 4B6S, which is 
reported here. 
The results for the DHQ2-Mt enzyme show that the relative position of ligand 4c, Arg19 and Tyr24 in the 
active site does not change significantly during the simulation (10 ns), suggesting that the interactions of the 
perfluorobenzyl moiety of 4c with the guanidinium group of Arg19 (electrostatic) and with the aromatic ring 
of Tyr24 (ππ stacking) are very strong and provide a very stable closed form of the loop. In fact, 
replacement of the perfluorobenzyl group by a 4-methoxybenzyl one causes, after approximately 1 ns of 
dynamic simulation, the displacement of the Arg19 side chain from the active site (~3 Å) while the side 
chain of Tyr24 remains reasonably close to the 4-methoxybenzyl moiety (see supporting information). 
An attempt by the side chain of Arg17 to enter into the active site was not observed in the MD simulations 
carried out with the binary complex DHQ2-Hp/4c. Moreover, the key ππ stacking interaction between the 
perfluorobenzyl group and the Tyr22 was maintained during the simulation, which shows once again the 
relevance of this interaction in the binding mode of ligand 4c in both enzymes. This key ππ stacking 
interaction is easily lost by replacement of the perfluorobenzyl group by a 4-methoxybenzyl one. Thus, after 
10 
approximately 3 ns of dynamic simulation, the aromatic ring of Tyr22 is clearly displaced away from the 4-
methoxybenzyl group, which could explain the lower inhibition potency of ligand 4a in comparison to 
ligand 4c (Figure 4). A more detailed analysis of the dynamic behavior of the loops of both enzymes 
allowed us to identify structural differences between the two loops that might explain the different binding 
mode of ligands 4 in the active site of both enzymes and the differences in their inhibition potency. It was 
found that the presence of a polar amino acid in the middle of the loop of the H. pylori enzyme, specifically 
Arg20, favors its organization by forming a set of attractive hydrogen bonds that reduces the flexibility of 
the loop. Such behavior was not observed for the DHQ2-Mt enzyme, which has an alanine in this position 
(see supporting information). These findings are more clearly shown in the dynamic simulation studies 
carried out with ligand 5c, which will be discussed below. 
Loop flexibility and movement differences. Using the enzyme geometries found in the crystal structures of 
compound 4c with both enzymes, the binding mode of 2R-perfluorobenzyl derivative 5c was studied. For 
the DHQ2-Mt enzyme, these studies suggest that the loop would adopt a similar conformation as for ligand 
4c. Thus, the perfluorobenzyl moiety would act as a bridge between the two essential residues, Tyr24 and 
Arg19, by establishing ππ stacking and electrostatic interactions, respectively. In contrast, for the H. pylori 
enzyme, after 1 ns of dynamic simulation a ππ stacking interaction with the essential Tyr22 was not 
observed. In contrast, the loop quickly adopts an open conformation that allows the rotation of the 
perfluorobenzyl group (~90º), which is now approximately perpendicular to the cyclohexane ring. It was 
observed that the conformation of the loop is clearly controlled by the formation of a key salt bridge 
between the side chains of residues Asp18 and Arg20 that, once formed, is maintained throughout the 
simulation period (Figure 5). Similar behavior was also observed in the simulation studies performed with 
ligand 4a (see above) although for ligand 5c it is clearly more pronounced considering the salt bridge 
distances, which in this case are 2.83.1 Å. The formation of a salt bridge between Asp18 and Arg20, 
together with the hydrogen bonds between the amide nitrogen of Pro19 and Leu21, might contribute 
significantly to reduce the mobility of the H. pylori loop and to control its movement. In fact, analysis of the 
amino acid sequence in various DHQ2 (see supporting information) reveals that the equivalent residues in 
the DHQ2-Mt enzyme are Glu20 and Ala22. The M. tuberculosis enzyme is the only DHQ2 that has a non-
11 
polar residue in this position, specifically Ala22, which prevents the formation of a similar salt bridge. For 
the H. pylori enzyme, the formation of the salt bridge between Asp18 and Arg20 also appears to promote the 
electrostatic interaction between the two essential residues of the loop, Arg17 and Tyr22, which remain 
close once formed (see supporting information). The latter interaction could also reduce the electron density 
of the phenol ring and therefore the possible ππ stacking interaction between the aromatic moiety of the 
ligand and the aromatic ring of Tyr22 residue would be weaker. This finding supports the idea that the 
essential arginine of the loop has also a crucial role in controlling the position and the appropriate 
orientation of Tyr22 residue. 
In contrast, the MD simulation studies carried out on the M. tuberculosis enzyme showed that the movement 
of the tyrosine side chain is not controlled by the essential arginine (see supporting information). Instead, its 
position could be mainly controlled by the interaction with the aromatic moiety of the ligand that for the 
perfluorobenzyl substrate analogs would be a ππ stacking one. This is also favored by a greater flexibility 
of the DHQ2-Mt loop that allows the tyrosine side chain to be closer to C2 of the substrate analogs. It is 
probable that, for the H. pylori enzyme, the formation of this salt bridge reduces the ability of its loop to 
accommodate the substituent present on C2 of the substrate analogs 4. As a consequence, changes to the 
benzyl group on C2 should have more pronounced effects on their corresponding inhibition potencies than 
for the DHQ2-Mt enzyme, as experimentally observed. 
The MD simulation studies also reveal significant changes in the interaction of ligand 5c in the active site of 
DHQ2-Hp with the conserved water involved in the enzymatic mechanism. Only for ligand 5c, the 
hydrogen-bonding interaction between its ketone group and the water molecule is lost during the simulation 
because the position relative to the catalytic water increases (see supporting information). As a consequence, 
the water molecule rotates by approximately 90º and is displaced toward the carbonyl group of Pro9 and the 
main-chain amide of Ala19. We recently showed that this hydrogen-bonding interaction makes an important 
contribution to the inhibition potency of mimics of the enol intermediate 3.
17 
We believe that this may also 
be the case for ligand 5c. 
Conclusions and Final Remarks. The structural changes caused by the substitution of the aromatic moiety 
in (2S)-2-benzyl-3-dehydroquinic acids 4 and its epimers 5 by electron-withdrawing or electron-donating 
12 
groups in type II dehydroquinase enzyme from M. tuberculosis and H. pylori has been investigated by 
structural and computational studies.  
The crystal structures of M. tuberculosis and H. pylori in complex with 2S-4-methoxybenzyl 4a and 2S-
perfluorobenzyl derivatives 4c have been solved at 2.0, 2.3, 2.0 and 1.9 Å, respectively. The crystal structure 
of M. tuberculosis in complex with 2R-benzothiophenyl derivative 5b is also reported at 1.55 Å. The 
structural studies reported here show that, for the DHQ2-Hp enzyme and regardless of the type of 
substituent of the aromatic ring, the binding mode of the 2S-2-benzyl derivatives 4 is quite similar, which 
could explain the similar inhibition constants obtained. In both cases, the essential Arg17, which is located 
on the loop that closes over the active site upon substrate binding, is expelled from the active site and faces 
away from the essential Tyr22, the residue that triggers the dehydration reaction. The essential arginine is 
presumed to orient the tyrosine in an appropriate manner for proton abstraction. In contrast, for the DHQ2-
Mt enzyme there are significant differences in the binding mode of these compounds 4 depending on the 
type of substituent of the aromatic ring, which mainly controls the position of the two essential residues 
located on the loop. In both compounds 4a and 4c there is a dramatic reduction of the loop flexibility, albeit 
by a different mechanism. Thus, the perfluorobenzyl derivative 4c causes the complete closure of the active 
site through the formation of a strong ππ stacking interaction with the aromatic ring of Tyr24. In contrast, 
the 4-methoxybenzyl derivative 4a favors a more open conformation of the loop, with Arg19 facing out of 
the active site. 
The dynamic behavior of both loops in binding 2S-2-benzyl derivatives 4 and their epimers, compounds 5, 
were investigated by MD simulations and this provided an understanding of the reduced mobility of the H. 
pylori loop. For the DHQ2-Mt enzyme, these studies suggest that the perfluorobenzyl moiety of 4c and its 
epimer 5c would act as a bridge between the two essential residues of the loop, Arg19 and Tyr24, through 
the establishment of strong electrostatic interactions between its fluorine atoms and the guanidinium group 
of Arg19 and by strong ππ stacking interactions with the aromatic ring of Tyr24. As a consequence, this 
perfluorobenzyl moiety does not block the entrance of the side chain of the arginine in the active site, as in 
previously reported PDB entry 2XB8
10
 containing 2S-4-methoxybenzyl compound 5a in the active site, i.e. a 
ligand with an electron-rich aromatic ring. In addition, the results allowed us to identify key structural 
13 
differences between the loops of the two enzymes. Specifically, the formation of a salt bridge between 
Asp18 and Arg20 together with the hydrogen bonds between the amide nitrogen of Pro19 and Leu21 in the 
DHQ2-Hp enzyme seems to contribute significantly to reducing the mobility of the H. pylori loop and to 
control its movement. The latter interactions could also allow the essential arginine to control the position 
and the orientation of the tyrosine side chain, which is not observed with the DHQ2-Mt enzyme. This fact 
could explain, for instance, the significantly higher inhibition constant of the pentafluorobenzyl analog 5c 
against DHQ2-Hp in comparison to the other compounds in these series’. For the M. tuberculosis enzyme, 
the MD simulations studies suggest that the movement and the higher flexibility of the loop allow the 
tyrosine side chain to freely interact with the aromatic moiety of inhibitors 4–5. For compounds substituted 
with electron-withdrawing groups, a closed conformation of the DHQ2-Mt loop is favored by establishing 
ππ stacking and electrostatic interactions with Tyr24 and Arg19, respectively. The latter is more difficult 
with the DHQ2-Hp enzyme due to the reduced mobility of its loop and to the interaction between Arg17 and 
Tyr22. For both enzymes, the aromatic moiety of those inhibitors 4–5 substituted with electron-donating 
groups block the entrance of the essential arginine side chain into the active site. These loop flexibility 
differences should make the DHQ2-Hp enzyme particularly sensitive to changes introduced in C2 of the 
natural substrate, because the loop should be less able to accommodate these changes than for the M. 
tuberculosis enzyme, differences that should be considered for future designs. 
 
EXPERIMENTAL SECTION 
Dehydroquinase Assays. Both enzymes were purified as described previously.
18,19 
Concentrated solutions 
of DHQ2-Hp (6.4 mg mL-1) or DHQ2-Mt (2.4 mg mL
-1
) were stored in potassium phosphate buffer (50 
mM, pH 7.2), DTT (1 mM) and NaCl (150 mM). When required for assays, aliquots of the enzyme stocks 
were diluted into water and buffer and stored on ice.
 
Dehydroquinase was assayed in the forward direction 
by monitoring the increase in absorbance at 234 nm in the UV spectrum due to the absorbance of the enone-
carboxylate chromophore of 3-dehydroshikimic acid (2) (/M-1 cm-1 12 000). Standard assay conditions 
were pH 7.0 at 25 ºC in Tris.HCl (50 mM) for DHQ2-Hp and Tris.HOAc (50 mM) for DHQ2-Mt. Each 
assay was initiated by addition of the substrate. Solutions of 3-dehydroquinic acid (1) were calibrated by 
14 
equilibration with DHQ2 and measurement of the change in the UV absorbance at 234 nm due to the 
formation of the enone-carboxylate chromophore of 3-dehydroshikimic acid (2). The Ki values of acids 45 
against DHQ2 were obtained from Dixon plots (1/v vs [I]) of assay data. The initial rates at fixed enzyme 
and substrate concentrations (0.25–1.4 Km) were measured in the absence and in the presence of various 
inhibitor concentrations. 
 
Crystallization of DHQ2-Hp/4a, DHQ2-Hp/4c and DHQ2-Mt/4c binary complexes. Solutions of freshly 
purified DHQ2-Hp and DHQ2-Mt were concentrated to 20 mg mL
–1
 in 50 mM Tris-HCl pH 7.5, 1 mM 2-
mercaptoethanol, 1 mM ethylenediaminetetraacetic acid (EDTA) and 200 mM sodium chloride. Compounds 
4a and 4c were dissolved at 0.25 M in methanol and added at a ratio of 1:20 (v/v) to aliquots of the 
concentrated protein solution to give solutions of approximately 10 equivalents of inhibitor per protein 
monomer. Diamond-shaped crystals of up to 0.2 mm × 0.2 mm of DHQ2-Hp/4a, DHQ2-Hp/4c and DHQ2-
Mt/4c complexes were obtained after one month of vapor diffusion in sitting drops comprised of 2.0 μL of 
protein/inhibitor solution mixed with 2.0 μL of reservoir solution equilibrated against 0.15 mL reservoirs 
containing 36% (w/v) polyethyleneglycol 4000 and 0.1 M sodium citrate pH 5.4, 32% (w/v) 
polyethyleneglycol 4000 and 0.1 M sodium citrate pH 5.4 and 20% (w/v) polyethyleneglycol 2000ME and 
0.1 M 3-(N-morpholino)propanesulfonic acid (MOPS) pH 6.5, respectively. 
Crystallization of DHQ2-Mt/4a and DHQ2-Mt/5b binary complexes. Apo-DHQ2-Mt crystals
4
 were 
soaked in 10 mM solutions of inhibitors 4a or 5b in the crystallization mixture [32% (v/v) 2-methyl-2,4-
pentanediol, 0.3 M ammonium sulfate and 0.1 M 4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic acid 
sodium salt (HEPES sodium salt), pH 7.5] for 24 h. 
Structure Determination of Binary Complexes. Crystals were flash-frozen directly from the 
crystallization mixtures by rapid immersion in liquid nitrogen. X-ray diffraction data for DHQ2-Mt/4a 
complex were collected on beamline ID14-1 (ESRF, Grenoble, France) and for DHQ2-Hp/4a and 4c 
complexes and DHQ-Mt/5b and 4c complexes were collected on beamline Proxima1 (Synchrotron Soleil, 





 and other programs within the CCP4 software suite.
22
 The structures of 




 with a search model generated from PDB entry 2C4V.
11
 Similarly, PDB entry 1H0S
12
 
was used for DHQ2-Mt binary complexes. Inhibitors’ structure and geometrical restraints were generated 
with the PRODRG2 server
24
 and were manually placed during the model building, which was performed 
with COOT.
25
 Reflections for calculating Rfree
26
 were selected in thin shells for DHQ2-Hp/4a and DHQ2-
Hp/4c data and randomly for DHQ2-Mt/5b, DHQ2-Mt/4a and DHQ2-Mt/4c data. Refinement of the model 
was performed with REFMAC
27
 and final structure validation was performed with MOLPROBITY.
28 
The 
data collection, refinement and model statistics are summarized in Table 2. Structure figures were prepared 
using PYMOL.
29 
Molecular dynamics simulations. Ligand minimization. Ligand geometries were optimized using a 
restricted Hartree–Fock (RHF) method and a 6–31G(d) basis set, as implemented in the ab initio program 
Gaussian 09.
30
 The resulting wavefunctions were used to calculate electrostatic potential-derived (ESP) 
charges employing the restrained electrostatic potential (RESP)
31 
methodology, as implemented in the 
assisted model building with energy refinement (AMBER)
32
 suite of programs. The missing bonded and 




Generation and minimization of the DHQ2-ligand complexes. Simulations were carried out using the 
enzyme geometries found in the crystal structure of the binary complexes DHQ2-Mt/4c (PDB code 4B6P) 
and DHQ2-Hp/4c (PDB code 4B6S). Taking into account that unfolding and refolding studies of DHQ2 
have shown that the trimer
34
 is the biological unit of the enzyme and on the basis of preliminary simulations 
on the monomer proving to be unstable under our simulation conditions, the trimer was used for these 
studies. Hydrogens were added to the protein using the web-based PROPKA3.1 server,
35-38
 which assigned 
protonation states to all titratable residues at the chosen pH of 7.0. However, δ and/or ε protonation was 
manually corrected for His102 (dual) of the active site due to mechanistic considerations and on the basis of 
results from preliminary MD simulations. Molecular mechanics parameters from the ff03 and GAFF force 
fields, respectively, were assigned to the protein and the ligands using the LEaP module of AMBER 10.0.
39 
All terminal hydrogens were first minimized in vacuum (2000 steps, half of them steepest descent, the other 
half conjugate gradient). Energy minimization was carried out in two stages using the implicit solvent GB 
16 
model; firstly protein side chains (2000 steps, half of them steepest descent, the other half conjugate 
gradient) and secondly the entire complex (2000 steps, idem). Thereafter each refined DHQ2-ligand 
complex was neutralized by addition of sodium ions and immersed in a truncated octahedron of TIP3P water 
molecules (10 Å radius).
39-41 
Simulations. MD simulations were performed using the AMBER 10.0 suite of programs and Amber ff03 
force field. Periodic boundary conditions were applied and electrostatic interactions were treated using the 
smooth particle mesh Ewald method (PME)
42
 with a grid spacing of 1 Å. The cutoff distance for the non-
bonded interactions was 9 Å. The SHAKE algorithm
43
 was applied to all bonds containing hydrogen, using a 
tolerance of 10
–5
 Å and an integration step of 2.0 fs. Minimization was carried out in three steps, starting 
with the octahedron water hydrogens, followed by solvent molecules and sodium counterions and finally the 
entire system. The minimized system was heated at 300 K (1 atm, 25 ps, a positional restraint force constant 








 (10 steps) 
and the resulting systems were allowed to equilibrate further. MD were carried out for 10 ns. System 
coordinates were collected every 20 ps for further analysis. A slow-cooling MD simulation was then 
performed (6 steps until 273 K, 0.2 ns each). Finally, minimization of the entire complexes was performed 
(100,000 steps, half of them steepest descent, the other half conjugate gradient). 
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Scheme 1. Enzymatic conversion of 3-dehydroquinic acid (1) to 3-dehydroshikimic acid (2) catalyzed by 
DHQ2. The reaction proceeds via an enol intermediate 3. Relevant residues are indicated (the numbering 






Table 1. Ki (nM) values for (2S)- 4 and (2R)-2-benzyl-3-dehydroquinic acids 5 against DHQ2-Mt and 
DHQ2-Hp and PDB accession codes.
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Compound Ar Ki PDB Ki PDB 
 
 
100 4B6O 1420 4B6R 
 
 
56 -- 900 -- 
 
 










28 4B6P 160 -- 
 
 
47 -- 2600 -- 
a
Km = 15 µM, kcat = 0.15 s
-1 
under assay conditions: Tris.HOAc (50 mM, pH 7.0, 25 
ºC). 
b
Km = 448 µM, kcat = 0.06 s
-1 










Figure 1. Unbiased electron density for inhibitors in binary complex: (a) DHQ-Mt/4a (PDB code: 4B6O); 
(b) DHQ-Mt/4c (PDB code: 4B6P); (c) DHQ-Mt/5b (PDB code: 4B6Q); (d) DHQ-Hp/4a (chain A, PDB 
code: 4B6R); (e) DHQ2-Hp/4c (chain A, PDB code: 4B6S). From the model obtained by molecular 
replacement and before inclusion of the inhibitor molecule, refinement was performed to obtain unbiased 
density for the inhibitor molecule and other model changes. A maximum-likelihood weighted 2Fo – Fc map 
contoured at 1σ is shown up to 1.6 Å around the inhibitor molecule (green). The final model [DHQ2-Mt 
(blue); DHQ2-Hp (gray)], including the inhibitor molecule [4a (cyan); 4c (orange); 5b (magenta)], is 
superposed onto the map. The loop is disordered in PDB entry 4B6Q. 
  
26 
Table 2. Crystallographic data collection and refinement statistics for the DHQ2 complexes with inhibitors 




 DHQ2-Mt/4a DHQ2-Mt/4c DHQ2-Mt/5b DHQ2-Hp/4a DHQ2-Hp/4c 





a = b = c = 126.19 a = b = c = 126.27 a = b = c = 126.27 a = b = 100.44, 
c = 104.30 
a = b = 100.19 
c = 104.58 
wavelength (Å) 0.93340 0.98011 0.98011 0.98011 0.98011 
detector ADSC Q210 CCD ADSC Q315r CCD ADSC Q315r CCD ADSC Q315r 
CCD 








































multiplicity 7.4 (7.4) 4.3 (4.3) 6.6 (5.8) 4.4 (3.9) 7.8 (6.8) 
completeness 1.000 (1.000) 1.000 (1.000) 0.999 (0.997) 0.997 (1.000) 0.998 (0.999) 




















10274 (1492) 7144 (1025) 23379 (3387) 34582 (4973) 41125 (6017) 
reflections used 
for Rfree 
1104 (151) 1025 (55) 1296 (178) 1876 (248) 1180 (21) 
R-factor
f
 0.144 (0.157) 0.169 (0.211) 0.134 (0.176) 0.212 (0.270) 0.226 (0.385) 
Rfree
g
 0.178 (0.212) 0.223 (0.312) 0.166 (0.217) 0.276 (0.330) 0.278 (0.415) 
rmsd (bonds 
(Å)/angles (deg)) 

























95.7/98.6 96.4/100.0 98.5/100.0  95.1/99.4 96.1/99.4  
PDB accession 
code 
4B6O 4B6P 4B6Q 4B6R 4B6S 
a
Results from SCALA (ref. 25). 
b
One Ångstrom (Å) is 0.1 nm. 
c
No σ cut-off or other restrictions were used for 
inclusion of reflections. 
d
Values in parentheses are for the highest resolution bin, where applicable. 
e
Results from 




= ||Fobs(hkl)|  |Fcalc(hkl)|| / |Fobs(hkl)|. 
g
According to Brünger (ref. 30). 
h
According to the program MOLPROBITY (ref. 32). The percentages indicated are for residues in favored and total 







Figure 2. Relevant binding interactions of the perfluorobenzyl moiety of inhibitor 4c in the 
enzymeinhibitor crystal structure of DHQ2-Mt (PDB code: 4B6P). Hydrogen-bonding interactions and 







Figure 3. Relevant binding interactions of the benzyl moiety of inhibitor 4c in the enzymeinhibitor crystal 
structure of DHQ2-Hp (PDB code: 4B6S). Hydrogen-bonding interactions (red), π-π interactions (magenta) 







Figure 4. Binding mode of ligand 4a (yellow) in the active site of DHQ2-Hp obtained by MD simulations: 
(a) after minimization and prior to simulation; (b) after 10 ns of MD. Simulations were carried out using the 
enzyme geometries found in the crystal structure of DHQ2-Hp/4c binary complex (PDB entry 4B6S). 
Hydrogen-bonding interaction between several residues of the loop is highlighted. Relevant side chain 







Figure 5. Binding mode of ligand 5c in the active site of DHQ2-Hp (violet) obtained by MD simulations: 
(a) after minimization and prior to simulation; (b) after 10 ns of MD. Hydrogen-bonding interactions 
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